Estrella Non Current Liabilities Other from 2010 to 2024

ESLAW Stock   0.09  0  3.53%   
Estrella Immunopharma Non Current Liabilities Other yearly trend continues to be fairly stable with very little volatility. Non Current Liabilities Other will likely drop to about 11 K in 2024. During the period from 2010 to 2024, Estrella Immunopharma Non Current Liabilities Other regression line of quarterly data had mean square error of  982,226 and geometric mean of  14,142. View All Fundamentals
 
Non Current Liabilities Other  
First Reported
2010-12-31
Previous Quarter
11.5 K
Current Value
11 K
Quarterly Volatility
1.3 K
 
Credit Downgrade
 
Yuan Drop
 
Covid
Check Estrella Immunopharma financial statements over time to gain insight into future company performance. You can evaluate financial statements to find patterns among Estrella Immunopharma's main balance sheet or income statement drivers, such as Tax Provision of 1.7 K, Depreciation And Amortization of 246.2 K or Selling General Administrative of 3.4 M, as well as many indicators such as Price To Sales Ratio of 0.0, Dividend Yield of 0.0 or PTB Ratio of 8.39. Estrella financial statements analysis is a perfect complement when working with Estrella Immunopharma Valuation or Volatility modules.
  
Check out Investing Opportunities to better understand how to build diversified portfolios. Also, note that the market value of any company could be closely tied with the direction of predictive economic indicators such as signals in nation.

Latest Estrella Immunopharma's Non Current Liabilities Other Growth Pattern

Below is the plot of the Non Current Liabilities Other of Estrella Immunopharma over the last few years. It is Estrella Immunopharma's Non Current Liabilities Other historical data analysis aims to capture in quantitative terms the overall pattern of either growth or decline in Estrella Immunopharma's overall financial position and show how it may be relating to other accounts over time.
Non Current Liabilities Other10 Years Trend
Slightly volatile
   Non Current Liabilities Other   
       Timeline  

Estrella Non Current Liabilities Other Regression Statistics

Arithmetic Mean14,206
Geometric Mean14,142
Coefficient Of Variation9.32
Mean Deviation989.60
Median14,825
Standard Deviation1,324
Sample Variance1.8M
Range3.8K
R-Value(0.69)
Mean Square Error982,226
R-Squared0.48
Significance0
Slope(204.89)
Total Sum of Squares24.5M

Estrella Non Current Liabilities Other History

202411 K
202311.5 K
202212.7 K

About Estrella Immunopharma Financial Statements

Estrella Immunopharma investors use historical fundamental indicators, such as Estrella Immunopharma's Non Current Liabilities Other, to determine how well the company is positioned to perform in the future. Understanding over-time patterns can help investors decide on long-term investments in Estrella Immunopharma. Please read more on our technical analysis and fundamental analysis pages.
Last ReportedProjected for Next Year
Non Current Liabilities Other11.5 K11 K

Also Currently Popular

Analyzing currently trending equities could be an opportunity to develop a better portfolio based on different market momentums that they can trigger. Utilizing the top trending stocks is also useful when creating a market-neutral strategy or pair trading technique involving a short or a long position in a currently trending equity.

Additional Tools for Estrella Stock Analysis

When running Estrella Immunopharma's price analysis, check to measure Estrella Immunopharma's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Estrella Immunopharma is operating at the current time. Most of Estrella Immunopharma's value examination focuses on studying past and present price action to predict the probability of Estrella Immunopharma's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Estrella Immunopharma's price. Additionally, you may evaluate how the addition of Estrella Immunopharma to your portfolios can decrease your overall portfolio volatility.